---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-240757"
form_type: "8-K"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T12:08:00.190661+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# XOMA Royalty acquires 50% of Twist Bioscience's royalty/milestone economics for $15M

## Summary
- Acquired 50% economic interest in milestones/royalties from Twist's 60+ early-stage programs across 30 partners for $15M upfront.
- XOMA's portfolio now exceeds 100 assets, spanning commercial to pre-clinical programs.
- Twist's Biopharma Solutions business unit yields future payments under biopharma services agreements.
- Chief Investment Officer Brad Sitko cites potential for superior risk-adjusted returns.
- Gibson, Dunn & Crutcher served as XOMA's legal advisor.

## SEC filing metadata
- accession: 0001193125-24-240757
- form_type: 8-K
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312524240757/0001193125-24-240757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312524240757/d826403d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-240757
- JSON: https://secwatch.observer/filing/0001193125-24-240757.json
- Plain text: https://secwatch.observer/filing/0001193125-24-240757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.